1. Signaling Pathways
  2. GPCR/G Protein
  3. GnRH Receptor

GnRH Receptor

Gonadotropin releasing hormone receptor; GNRHR

The GnRH receptor (Gonadotropin-releasing hormone receptor, GNRHR) is a member of the rhodopsin-like G protein-coupled receptor (GPCR) family and consists of seven transmembrane helical domains connected via extra- and intra-cellular segments. GnRH receptor is located on the plasma membrane of gonadotrophs, pituitary cells that synthesize the gonadotrophins LH and FSH.

Mammalian type I and II GnRH receptors show differential ligand preference for GnRH-I (also named as LHRHR) and GnRH-II, respectively. All GnRH receptors activate the Gq/11 family of G proteins, which activate phospholipase C-catalyzed production of second messengers that activate protein kinase C (PKC). GnRH receptor activated by GnRH analogues stimulates the synthesis and release of LH and FSH. GnRH receptors can be used for the research of breast and prostate cancer, regulation of fertility, endometriosis and a range of other medical and veterinary uses.

GnRH Receptor Related Products (94):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152856
    Merigolix
    Antagonist
    Merigolix is a potent gonadotrophin releasing hormone (GnRH) antagonist.
    Merigolix
  • HY-16168B
    Degarelix acetate hydrate
    Antagonist
    Degarelix acetate hydrate is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research.
    Degarelix acetate hydrate
  • HY-133080
    BAY-784
    Antagonist
    BAY-784 is a gonadotropin releasing hormone receptor (GnRH-R) antagonist probe with IC50s of 21 and 24 nM for human and rat GnRH-R, respectively.
    BAY-784
  • HY-105173
    Teverelix
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer.
    Teverelix
  • HY-P4564
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
    (D-Ser(tBu)6,D-Leu7,Azagly10)-LHRH
  • HY-P4190
    Fsh receptor-binding inhibitor fragment(bi-10)
    Antagonist
    FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries.
    Fsh receptor-binding inhibitor fragment(bi-10)
  • HY-P3605
    GnRH Associated Peptide (25-53), human
    Activator
    GnRH Associated Peptide (GAP) (25-53), human is the human gonadotropin-releasing hormone-associated peptide (GAP) 25-53 fragment (hGAP-25-53), can be used as immunogen to generate antiseras including MC-1, MC-2, and MC-3. GAP is joined to the luteinizing hormone-releasing hormone (LH-RH) sequence by a 3 amino acid processing site.
    GnRH Associated Peptide (25-53), human
  • HY-P4688
    (Ser(Ac)4,D-Ser(tBu)6,Azagly10)-LHRH
    (Ser(Ac)4,D-Ser(tBu)6,Azagly10)-LHRH is an important peptide hormone.
    (Ser(Ac)4,D-Ser(tBu)6,Azagly10)-LHRH
  • HY-P3583
    (Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken)
    Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken) is an active petide. (Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken) can be used for the research of various biochemical studies.
    (Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken)
  • HY-P4739
    LHRH (1-5) (free acid)
    LHRH (1-5) (free acid) is a polypeptide generated by the cleavage of LHRH at the Tyr55-Gly66 site. LHRH (1-5) (free acid) is converted into LHRH (1-3) and LHRH (4-5) fragments under the catalysis of Angiotensin-converting enzyme (HY-P2983).
    LHRH (1-5) (free acid)
  • HY-107534
    AG-045572
    Antagonist 99.52%
    AG-045572 is a GnRH receptor antagonist with Kis of 6.0 nM and 3.8 nM for human and rat GnRH receptor, respectively. AG-045572 is metabolized by CYP3A and ressuppresses testosterone.
    AG-045572
  • HY-16532
    Zoptarelin doxorubicin
    Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro.
    Zoptarelin doxorubicin
  • HY-14369S
    Elagolix-13C,d3 sodium
    Antagonist
    Elagolix-13C,d3 (sodium) is the 13C- and deuterium labeled Elagolix sodium. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.
    Elagolix-<sup>13</sup>C,d<sub>3</sub> sodium
  • HY-16168AS
    Degarelix-d7
    Antagonist
    Degarelix-d7 is deuterium labeled Degarelix. Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.
    Degarelix-d<sub>7</sub>
  • HY-P0056
    Histrelin
    Agonist
    Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis.
    Histrelin
  • HY-P3606
    GnRH Associated Peptide (1-24), human
    Activator
    GnRH Associated Peptide (GAP) (1-24), human is the human gonadotropin-releasing hormone-associated peptide (GAP) 1-24 fragment (hGAP-1-24). GAP is joined to the luteinizing hormone-releasing hormone (LH-RH) sequence by a 3 amino acid processing site.
    GnRH Associated Peptide (1-24), human
  • HY-P4568
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH
  • HY-P3675
    LH-RH (4-10)
    Activator
    LH-RH (4-10) is a heptapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (4-10) produced in macrophages and type II pneumocytes.
    LH-RH (4-10)
  • HY-P3671
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH
    Antagonist
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist.
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH
  • HY-P4693
    (Ser(tBu)6,Azagly10)-LHRH
    (Ser(tBu)6,Azagly10)-LHRH is a potent aza-GLY analog.
    (Ser(tBu)6,Azagly10)-LHRH